Clinical trial
A Randomized Phase III Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatinum-Based Chemoradiotherapy [PARADIGM TRIAL]
NCT00095875 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatinum-Based Chemoradiotherapy [PARADIGM TRIAL]
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2004
- Completion date
- April 30, 2012
- Enrollment
- 145 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
head and neck cancer